Avalere is presenting at Asembia’s 2022 Specialty Pharmacy Summit, and Ryan Urgo, MPAP, managing director, health policy, discusses possible drug pricing policy options on the table for the Biden administration to consider in a midterm election year.
Avalere is presenting at Asembia’s 2022 Specialty Pharmacy Summit, and Ryan Urgo, MPAP, managing director, health policy, is one of the panel members who will discuss possible drug pricing policy options and other health care issues for the Biden administration to consider, in a talk called “Evolution of Biden’s Healthcare Agenda in an Election Year.”
Every administration wants to tackle high drug prices. What is Biden’s plan to move forward from Build Back Better and introduce and implement policies that do address prescription drug prices?
I think that the first order of business for the administration is to see if the legislative process bears fruit before the midterm elections. And they would try to get something done on Medicare negotiation, inflation, rebate penalties, and potentially Medicare Part D redesign. If that effort fails, it would be a safe bet to expect the administration pivots towards using their regulatory authority to try to get some of these similar policies through, but that would be through the confines of a demonstration through CMMI [Center for Medicare and Medicaid Innovation], potentially, and it would be a piecemeal effort and certainly much more limited in scope.